Callahan Advisors LLC Purchases Shares of 866 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Callahan Advisors LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 866 shares of the biopharmaceutical company's stock, valued at approximately $617,000.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Cardinal Capital Management boosted its holdings in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Cardinal Capital Management now owns 7,871 shares of the biopharmaceutical company's stock valued at $5,607,000 after purchasing an additional 36 shares during the last quarter. Kestra Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 104.5% in the fourth quarter. Kestra Investment Management LLC now owns 1,260 shares of the biopharmaceutical company's stock valued at $898,000 after purchasing an additional 644 shares during the last quarter. Atria Wealth Solutions Inc. boosted its holdings in Regeneron Pharmaceuticals by 5.7% in the fourth quarter. Atria Wealth Solutions Inc. now owns 1,734 shares of the biopharmaceutical company's stock valued at $1,235,000 after purchasing an additional 93 shares during the last quarter. Kornitzer Capital Management Inc. KS purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $600,000. Finally, Truist Financial Corp boosted its holdings in Regeneron Pharmaceuticals by 59.8% in the fourth quarter. Truist Financial Corp now owns 59,303 shares of the biopharmaceutical company's stock valued at $42,243,000 after purchasing an additional 22,192 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

REGN traded up $4.31 during trading hours on Friday, hitting $700.33. The company's stock had a trading volume of 727,332 shares, compared to its average volume of 923,518. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $76.56 billion, a PE ratio of 18.29, a PEG ratio of 2.30 and a beta of 0.08. The company has a 50-day simple moving average of $700.02 and a 200 day simple moving average of $886.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same period last year, the firm earned $11.86 EPS. The firm's revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. StockNews.com downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, November 4th. Bank of America reaffirmed an "underperform" rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Citigroup reduced their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Finally, Sanford C. Bernstein reduced their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.